Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers
Open Access
- 22 June 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (4) , 824-835
Abstract
Chloroquine and azithromycin were developed in combination for the preventive treatment of malaria in pregnancy, and more recently were proposed as coronavirus disease 2019 (COVID‐19) treatment options. Billions of doses of chloroquine have been administered worldwide over the past 70 years but concerns regarding cardiotoxicity, notably the risk of torsades de pointes (TdP), remain. This investigation aimed to characterize the pharmacokinetics and electrocardiographic effects of chloroquine and azithromycin observed in a large previously conducted healthy volunteer study. Healthy adult volunteers (n = 119) were randomized into 5 arms: placebo, chloroquine alone (600 mg base), or chloroquine with either 500 mg, 1,000 mg, or 1,500 mg of azithromycin all given daily for 3 days. Chloroquine and azithromycin levels, measured using liquid‐chromatography tandem mass spectrometry, and electrocardiograph intervals were recorded at frequent intervals. Time‐matched changes in the PR, QRS, and heart rate‐corrected JT, and QT intervals were calculated and the relationship with plasma concentrations was evaluated using linear and nonlinear mixed‐effects modeling. Chloroquine and azithromycin pharmacokinetics were described satisfactorily by two‐ and three‐compartment distribution models, respectively. No drug–drug interaction between chloroquine and azithromycin was observed. Chloroquine resulted in concentration‐dependent prolongation of the PR, QRS, JTc and QTc intervals with a minimal additional effect of azithromycin. QRS widening contributed ~ 28% of the observed QT prolongation. Chloroquine causes significant concentration‐dependent delays in both ventricular depolarization and repolarization. Co‐administration of azithromycin did not significantly increase these effects. The arrhythmogenic risk of TdP associated with chloroquine may have been substantially overestimated in studies which did not separate electrocardiograph QRS and JT prolongation.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV‐006052)
- Wellcome Trust (220211)
This publication has 48 references indexed in Scilit:
- Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potentialHeart Rhythm, 2015
- Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tabletsMalaria Journal, 2014
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy VolunteersPLoS Clinical Trials, 2007
- Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongationThe AAPS Journal, 2005
- Mass Treatment with Single-Dose Azithromycin for TrachomaNew England Journal of Medicine, 2004
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- Prognostic Significance of Corrected QT and Corrected JT Interval for Incident Coronary Heart Disease in a General Population Sample Stratified by Presence or Absence of Wide QRS ComplexCirculation, 2003